Legacy Healthcare SA

Legacy Healthcare SA is a Swiss biopharmaceutical company focused on creating prescription botanical drugs for serious medical conditions, particularly utilizing plant-derived compounds to address unmet medical needs. Founded in 2005 in Lausanne, Switzerland, Legacy Healthcare SA specializes in biopharmaceutical development. The company experienced a pivotal shift with its focus on prescription botanical drugs. The founders, Geert Cauwenbergh, Johanne Barthelet-Harti, and Saad Harti, laid the groundwork for the company's innovative approach.

As of November 24, 2017, Legacy Healthcare raised CHF 2 million in Series B funding from Maxhealth Medicine Group Co. , Ltd. , bringing the total amount raised to CHF 2 million. Legacy Healthcare is a Swiss-based biopharmaceutical company that specializes in developing prescription botanical drugs designed to treat serious medical conditions, particularly through the use of plant-derived compounds.

The company’s primary product candidate, CINAINU, targets alopecia areata, a chronic autoimmune disorder characterized by hair loss, which significantly affects patients' psychological and social well-being, especially children. CINAINU has demonstrated robust safety and efficacy in a phase 2/3 clinical trial. The company’s clientele includes healthcare providers and patients across various geographical markets, including the United States, Europe, and Japan, where they focus on delivering innovative solutions for managing alopecia areata and potentially other dermatological conditions in the future. Legacy Healthcare's revenue model is built around partnerships with healthcare providers and pharmaceutical distributors, facilitating the sale of their flagship product, CINAINU, through both direct-to-consumer avenues and B2B channels.

The company engages in strategic agreements or collaborations with healthcare institutions and pharmacies to ensure the availability of its products in targeted markets. Revenue transactions are structured around product sales, with potential frameworks for ongoing supply agreements with healthcare entities and pricing strategies tailored to different regions and patient demographics. The focus is on capturing market share in the biopharmaceutical sector through innovative product offerings that respond to unmet medical needs, particularly in areas such as dermatology and autoimmune disorders. In November 2017, Legacy Healthcare SA raised CHF 2 million in Series B funding from Maxhealth Medicine Group Co.

, Ltd. This investment will support the continued development of their primary product, CINAINU, as well as the exploration of new botanical drug candidates aimed at addressing other serious medical conditions. The company plans to expand its presence in the United States, Europe, and Japan, with strategic initiatives aimed at entering additional markets by 2025. These efforts will be bolstered by recent funding to enhance research and development capabilities and strengthen partnerships with healthcare institutions.